This Post-market clinical follow-up (PMCF) study is designed as retrospective, multi-center study to collect real-life data. A multi-center design is used to ensure a representative sample of the physicians who have performed the procedure and to provide a reasonable enrolment period for the required data to be collected. The rationale of this study is to confirm and support the clinical safety and performance of any of these products in a real-word population of 200 patients who underwent an endovascular intervention within standard-of-care (SOC) where at least 1 of the products (named above) from Cordis US Corp were used.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Primary Safety Endpoint: Freedom from Serious Adverse Events and Serious Adverse Device Effects
Timeframe: 30 days after procedure
Primary Efficacy Endpoint: Successful crossing, instroduction and deployment
Timeframe: 30 days post procedure
Primary Efficacy Endpoint: Successful crossing, instroduction and deployment
Timeframe: 30 days post procedure
Primary Efficacy Endpoint: Successful crossing, instroduction and deployment
Timeframe: 30 days post procedure
Primary Efficacy Endpoint: Successful crossing, instroduction and deployment
Timeframe: 30 days post procedure
Primary Efficacy Endpoint: Successful crossing, instroduction and deployment
Timeframe: 30 days post procedure
Primary Efficacy Endpoint: Successful crossing, instroduction and deployment
Timeframe: 30 days post procedure
Primary Efficacy Endpoint: Successful crossing, instroduction and deployment
Timeframe: 30 days post procedure
Primary Efficacy Endpoint: Successful crossing, instroduction and deployment
Timeframe: 30 days post procedure
Primary Efficacy Endpoint: Successful crossing, instroduction and deployment
Timeframe: 30 days post procedure
Primary Efficacy Endpoint: Successful crossing, instroduction and deployment
Timeframe: 30 days post procedure
Primary Efficacy Endpoint: Successful crossing, instroduction and deployment
Timeframe: 30 days post procedure
Primary Efficacy Endpoint: Successful crossing, instroduction and deployment
Timeframe: 30 days post procedure
Primary Efficacy Endpoint: Successful crossing, instroduction and deployment
Timeframe: 30 days post procedure
Primary Efficacy Endpoint: Successful crossing, instroduction and deployment
Timeframe: 30 days post procedure
Primary Efficacy Endpoint: Successful crossing, instroduction and deployment
Timeframe: 30 days post procedure